JP2022014891A - Foaming drug efficacy-imparting composition and drug efficacy imparting method using the same - Google Patents

Abstract

To provide a foaming drug efficacy-imparting composition to be packed in a spray product, capable of exhibiting excellent diffusibility of an active ingredient even without increasing foam retention, the foaming drug efficacy-imparting composition capable of exerting excellent drug efficacy as well as having a superior use feeling.SOLUTION FOR THE PROBLEM: A foaming drug efficacy-imparting composition to be packed in a spray product includes: (A) an active ingredient, (B) surfactant, (C) organic solvent, and water. When the composition is sprayed for one second to a 300-mL measuring cylinder with a bottom area 11.3 cm2, a foam volume ratio of a maximum value X of a cubic volume of a foam immediately after spraying and a cubic volume Y of the foam one minute after the spraying is Y/X≤0.99.SELECTED DRAWING: None

Description

The present invention relates to an effervescent medicinal effect-imparting composition and a medicinal effect-imparting method using the same.

Many effervescent products have a favorable usability because the appearance of the foam can be visually recognized at the time of use. Therefore, various types of effervescent products have been studied and developed conventionally.

For example, in Patent Document 1, bubbles that do not dry for a long time can be formed, and the bubbles remain on the surface of the malodor source without being dried for a long time, and the malodor source is covered with the bubbles to put the malodor into the air. Effervescent deodorant aerosol compositions that can prevent diffusion have been described. Further, Patent Document 2 describes an effervescent aerosol composition in which the undiluted solution to be ejected becomes foamy, the foaming property is good even at normal temperature and low temperature, and the sustainability is excellent, so that it is easy to use. There is.

However, the aerosol compositions described in Patent Document 1 and Patent Document 2 are both designed to enhance the sustainability of foam after foaming, and the exposure time to the object is increased by enhancing the sustainability of foam. It is said that it becomes longer and can fully demonstrate its performance. Further, it has been considered that the aerosol composition having poor foam sustainability may not be able to sufficiently exhibit its performance because the exposure time to the object is shortened. Therefore, an aerosol composition that can exert an excellent medicinal effect without increasing the durability of foam has been desired.

Japanese Unexamined Patent Publication No. 11-206868 Japanese Unexamined Patent Publication No. 2019-210302

The present invention has been made in view of the above problems, and in an effervescent medicinal effect-imparting composition for filling a jet product, it exhibits excellent diffusivity of the active ingredient without increasing the sustainability of foam. An object of the present invention is to provide an effervescent medicinal effect-imparting composition that can exhibit excellent medicinal properties and has an excellent usability.

As a result of diligent studies to achieve the object of the present invention, the present inventors have found that the foam volume, which is the rate of change in the volume of foam after injection, in the effervescent medicinal effect-imparting composition for filling the injected product. We have found that a specific range of ratio is important for improving the diffusivity, medicinal effect, and usability of the active ingredient, and have completed the present invention.

The present invention has been found that the following configuration exerts an excellent effect in achieving the above object.
(1) In an effervescent medicinal effect-imparting composition for filling a jet product,
The composition contains (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water.
It is a ratio of the maximum value X of the volume of foam immediately after injection and the volume Y of foam 1 minute after injection when the composition is injected into a 300 mL graduated cylinder having a bottom area of 11.3 cm ² for 1 second. An effervescent medicinal effect-imparting composition having a foam volume ratio of Y / X ≦ 0.99.
(2) The effervescent medicinal effect-imparting composition according to (1), wherein the organic solvent (C) is one or more selected from the group consisting of a hydrocarbon solvent, an alcohol solvent, and a glycol solvent. ..
(3) The effervescent medicinal effect-imparting composition according to (1) or (2), wherein the organic solvent (C) is blended in an amount of 0.5 to 30% by mass.
(4) The effervescent medicinal effect according to any one of (1) to (3), wherein the weight ratio of the active ingredient (A) to the organic solvent (C) is 10 ≦ (C) / (A) ≦ 700. Granting composition.
(5) The effervescent medicinal effect-imparting composition according to any one of (1) to (4), wherein Y / X is Y / X ≦ 0.70.
(6) The effervescent medicinal effect-imparting composition according to any one of (1) to (5), wherein the pH of the composition is 5.0 to 12.0.
(7) The effervescent medicinal effect-imparting composition according to any one of (1) to (6), wherein the surfactant is a nonionic surfactant and / or an amphoteric surfactant.
(8) The effervescent medicinal effect-imparting composition according to any one of (1) to (7), wherein the active ingredient (A) is an aromatic deodorant component and the medicinal effect is an aromatic deodorant effect.
(9) The effervescent medicinal effect-imparting composition according to any one of (1) to (7), wherein the active ingredient (A) is an antifouling ingredient and the medicinal effect is an antifouling effect.
(10) The effervescent medicinal effect-imparting composition according to any one of (1) to (7), wherein the active ingredient (A) is an antifungal ingredient and the medicinal effect is an antifungal effect.
(11) An aerosol product obtained by filling an aerosol container with the composition according to any one of (1) to (10) above and a propellant.
(12) A spray product obtained by filling a spray container with the composition according to any one of (1) to (10) above.
(13) An effervescent medicinal effect-imparting composition containing (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water.
It is a ratio of the maximum value X of the volume of foam immediately after injection and the volume Y of foam 1 minute after injection when the composition is injected into a 300 mL graduated cylinder having a bottom area of 11.3 cm ² for 1 second. A method for imparting a medicinal effect by injecting an effervescent medicinal effect-imparting composition having a foam volume ratio of Y / X ≦ 0.99.

The effervescent medicinal effect-imparting composition of the present invention has excellent diffusivity of the active ingredient, can exhibit an excellent medicinal effect, and has an excellent usability, especially the active ingredient, without increasing the durability of the foam. When it is an fragrance deodorant component, an antifouling component, or an antifungal component, it has excellent diffusivity, can exert an excellent fragrance deodorant effect, and has an excellent usability. It is suitable for use in places where there is a problem, and its practicality is extremely high.

Hereinafter, the effervescent medicinal effect-imparting composition of the present invention and the medicinal effect-imparting method using the same will be described in detail. However, the present invention is not intended to be limited to the configurations described in the embodiments and examples described below. In the specification of the present application, "-" includes a boundary value.

The component (A) active ingredient used in the present invention is not particularly limited, and examples thereof include an aromatic deodorant component, an antifungal component, an insect repellent component, an antifouling component, an anti-slimy component, an antibacterial component, and a virus inactivating component. Will be. One or more of these components.

The fragrance deodorant component is not particularly limited, but a component that masks a bad odor, a component that changes a good scent by a harmonized effect, and the like, for example, a fragrance and an essential oil, are used. Examples of fragrances include limonene such as d-lymonen, pinen such as α-pinen and β-pinen, simen such as p-simen, hydrocarbon fragrances such as inden and cariophyllene, linalol, geraniol, citronellol, and l-menthol. Mentor, ethyllinalol, borneol, anis alcohol, β-phenethyl alcohol, p-menthan-3,8-diol, α-terpineol, γ-terpineol such as terpineol, 1-hexenol, cis-3-hexene-1- Aldehyde-based fragrances such as oar, tetrahydrogeraniol, santalinol, cinnamyl alcohol, and sedrol, cineol such as caraxolide, β-naphthylmethyl ether, 1,4-cineol, and 1,8-cineol, ambroxide, and p-cresylmethyl. Ether-based fragrances such as ether, phenol-based fragrances such as anetol, eugenol, isooigenol, vanillin, ethyl vanillin, octanal, nonanal, undecylaldehyde, undecanal, decylaldehyde, n-butylaldehyde, isobutylaldehyde, hexylaldehyde, citral. , Citroneral, benzaldehyde, cinnamic aldehyde, anis aldehyde, cumin aldehyde, adxal, amyl cinnamic aldehyde, cyclamen aldehyde and other aldehyde-based fragrances, muskketone, carboxylic, menton, cypress, camphor, acetophenone, butyrophenone, tonalide, α-ionone, β-ionone, α-methylionone, β-methylionone, α-isomethylionone, β-isomethylionone, γ-methylionone, γ-isomethylionone, damascon, α-damascon, β-damascon, acetylsedrene , Kashmeran, cis-jasmon, dihydrojasmon and other ketone fragrances, γ-butyrolactone, γ-nonalactone, γ-decalactone, γ-undecalactone, coumarin, cineol, ambred lid, jasmolactone and other lactone-based fragrances, geranyl Formate, octyl acetate, geranyl acetate, benzyl acetate, cinnamyl acetate, tetrahydrogeranyl acetate, menthyl acetate, linaryl acetate, butyl propionate, benzyl acetate, methyl benzoate, allylhexanoate, allylheptanoate, allylcyclohexanepro Pionate, allyl amylglycolate, amylvalerianate, ami Lusalicylate, isoamyl acetate, butyl acetate, ethyl butyrate, acetyl eugenol, isoamyl salicylate, allyl caproate, ethyl caproate, ethyl propionate, ethyl acetoacetate, methyl salicylate, citronellyl acetate, citronellyl formate, Ester-based fragrances such as cinnamyl acetate, stearyl acetate, stearyl propionate, sedrill acetate, turpinyl acetate, acetal-based fragrances such as amyl cinnamic aldehyde dimethyl acetal, citral dimethyl acetal, indol, geranyl nitrile, citronellyl nitrile, Examples thereof include acetaldehyde phenylethylpropyl acetate, tesalon, aurantyl, linalol oxide and the like. The above fragrance can be used alone, or a mixed fragrance in which two or more kinds are mixed can also be used. These are known as synthetic fragrances, extracted fragrances and the like.

Examples of essential oils are peppermint oil, orange oil, lemon oil, lavender oil, peppermint oil, eucalyptus oil, citronella oil, lime oil, yuzu oil, jasmine oil, cypress oil, green tea essential oil, neroli oil, geranium oil, petitgrain oil. , Lemongrass oil, cinnamon oil, lemon eucalyptus oil, thyme oil, perilla oil, petitgrain oil, pine oil, rose oil, rosemary oil, ginger brain oil, fragrant oil, clary sage oil, sandalwood oil, spare mint oil, star anis Oil, lavandin oil, oak moss oil, okotia oil, patchouli oil, tonka bean tincture, terepine oil, crocodile bean tincture, basil oil, nutmeg oil, clove oil, boad rose oil, cananga oil, cardamon oil, cassia oil, cedarwood oil, mandarin Oil, tangerine oil, anis oil, bay oil, coriander oil, elemi oil, fennel oil, galvanum oil, hiba oil, cypress oil, vetiver oil, bergamot oil, ylang ylang oil, grapefruit oil, abies oil, akjong oil, almond oil , Angelica root oil, pagel oil, mint oil, perch oil, boa barrose oil, kayabuchi oil, gananga oil, capsicum oil, caraway oil, celery oil,
Examples thereof include cognac oil, cumin oil, gilt oil, estgolan oil, garlic oil, ginger oil, hop oil, sage oil, terepine oil and the like. The essential oil can be used alone, or a component obtained by mixing two or more of the essential oils can also be used.

The antifungal component is not particularly limited, and is, for example, isopropylmethylphenol (IPMP), carbachlor, timol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, ortho. Phenol-based antifungal components such as phenylphenol, о-cresol, m-cresol, and p-cresol, benzalconium chloride, benzalconium metosulfate, benzalconium salt such as benzalconium organic acid salt, benzethonium chloride, etc. Benzethonium salt such as benzethonium metosulfate and benzethonium organic acid salt, cetylpyridinium salt such as cetylpyridinium chloride, cetylpyridinium metosulfate, cetylpyridinium organic acid salt, didecyldimethylammonium chloride such as didecyldimethylammonium chloride and decyldimethylammonium metosulfate. Salts, dilauryldimethylammonium salts such as dilauryldimethylammonium chloride, dilauryldimethylammonium metosulfate, distearyldimethylammonium salts such as distearyldimethylammonium chloride, distearyldimethylammonium metosulfate, and 1,4-bis [3 , 3'-(1-decylpyridinium) methyloxy] butane dibromide, 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butanedichloride, 1,4-bis [3,3' -(1-decylpyridinium) methyloxy] 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butane salt and other cationic surfactant-based antifungal components, bigwanide Antifungal ingredient, azole antifungal ingredient such as tebuconazole, enilconazole, fruit seed extract such as grapefruit seed extract, oyster seed extract, grape seed extract, etc. Glycerin monofatty acid ester-based antifungal component, chlorhexyzingurconate, chlorhexidine salt such as chlorhexididi hydrochloride, chlorhexidine-based antifungal component such as chlorhexidine, octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, dodecyldimethyl (3-) Triethoxysilylpropyl) ammonium chloride, dodecyldiisopropyl (3-triethoxy) Cyrilpropyl) ammonium chloride, tetradecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, Pentadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldimethyl (3-) Triethoxysilylpropyl) ammonium chloride, hexadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, octadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride , Octadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride and other silicon-based antifungal components, benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, polylysine and other carboxylics. Acid-based antifungal components or salts thereof, dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver zeolite and other silver-based antifungal components, zincpyrythion, thiamine lauryl sulfate , Shirako protein, hydroxyalkylchitosan or a salt thereof, antifungal fragrance and the like. The antifungal component can be used alone, or a mixture of two or more of the antifungal components can also be used.

The insect repellent component is not particularly limited, and is, for example, phenothrin, etofenprox, silafluofen, permethrin, cypermethrin, transfluthrin, methfurthrin, profluthrin, empentrin, cypermethrin, ciphenotrin, allethrin, prarethrin, phthalthrin, imiprothrin, Pyrethroid insect repellents such as trin, mepafluthrin, heptafluthrin, tefluthrin, resmethrin, flamethrin, pyrethrin, acrinathrin, bifentrin, deltamethrin, tetramethrin, dinotefuran, imidacloprid, clothianidin, etc. Examples thereof include ethyl butylacetylaminopropionate (IR3535), p-menthan-3,8-diol, menthyl acetate, and peppermint oil. The insect repellent component can be used alone, or a component in which two or more kinds of the insect repellent components are mixed can also be used.

The antifouling component is not particularly limited, and is, for example, an alkyl glycoside antifouling component such as octyl glucoside, decyl glucoside, lauryl glucoside, myristyl glucoside, and cetyl glucoside, cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, and cetyltrimethyl. Tertiary ammonium salt-based antifouling components such as ammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, dimyristyldimethylammonium chloride, dimyristyldimethylammoniummethylsulfate, and didecyldimethylammoniummethsulfate, dimethyldiallylammonium chloride homopolymer Or, a quaternary ammonium salt polymer-based antifouling component such as a copolymer of a quaternary ammonium salt such as dimethyldiallylammonium chloride and an acrylic acid derivative such as acrylamide, acrylic acid, and acrylate, α-perfluorononenyloxy-ω-methylpoly. Fluorine-based antifouling components such as ethylene oxide, fluorinated alkyl hydrophilic group-containing oligomers, fluorinated alkyl ester addition polymers, fluorine-substituted glycols such as partially fluorinated alcohol-substituted glycols, alkylene oxide adducts of acetylene glycol, polyether-modified poly Examples thereof include siloxane, ethylenediamine tetraacetic acid and its salts, nitrilotriacetic acid and its salts, gluconic acid and its salts. The antifouling component can be used alone, or a mixture of two or more of the antifouling components can also be used.

The slime-proof component is not particularly limited, and examples thereof include allyl isothiocyanate and trichloroisocyanuric acid. The slime-proof component can be used alone, or a mixture of two or more of the slime-proof components can also be used.

The antibacterial component is not particularly limited, and is, for example, isopropylmethylphenol (IPMP), carbachlor, timol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, orthophenyl. Phenol-based antibacterial components such as phenol, о-cresol, m-cresol, and p-cresol, benzalconium salts such as benzalconium chloride, benzalconium metosulfate, and benzalconium organic acid salt, benzethonium chloride, benzethonium meth. Benzetnium salts such as sulfate and benzethonium organic acid salt, cetylpyridinium chloride such as cetylpyridinium chloride, cetylpyridinium methsulfate, cetylpyridinium salt such as cetylpyridinium organic acid salt, didecyldimethylammonium salt such as didecyldimethylammonium chloride and decyldimethylammonium metosulfate, Dilauryldimethylammonium salts such as dilauryldimethylammonium chloride and dilauryldimethylammonium metosulfate, distearyldimethylammonium salts such as distearyldimethylammonium chloride and distearyldimethylammonium metosulfate, and 1,4-bis [3,3 ´－ (1-decylpyridinium) methyloxy] butane dibromide, 1,4-bis [3,3 ′-(1-decylpyridinium) methyloxy] butanedichloride, 1,4-bis [3,3 ′-( 1-decylpyridinium) methyloxy] Butane dimethosulfate and other 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butane salts and other cationic surfactant-based antibacterial components, bigwanide-based antibacterial components , Tebuconazole, Enylconazole and other azole antibacterial components, Grapefruit seed extract, oyster seed extract, grape seed extract and other fruit seed extract type antibacterial components, monolaurin, monocaprin, monocapriline and other glycerin monofatty acid ester type Antibacterial component, chlorhexidine salt such as chlorhexidine gluconate, chlorhexididi hydrochloride, chlorhexidine antibacterial component such as chlorhexidine, octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, dodecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, Dodecyldiisopropyl (3-triethoxysilylpropyl) Ammonium chloride, tetradecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldimethyl (3-Triethoxysilylpropyl) ammonium chloride, pentadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldimethyl (3-triethoxysilyl) Propyl) ammonium chloride, hexadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, octadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, octadecyldi Silicon-based antibacterial components such as -n-propyl (3-triethoxysilylpropyl) ammonium chloride, carboxylic acid-based antibacterial components such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, and polylysine. Or their salts, dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver-based antibacterial components such as silver zeolite, zincpyrythion, thiamine lauryl sulfate, shirako protein, hydroxyalkylchitosan or The salt and the like can be mentioned. The antibacterial component can be used alone, or a mixture of two or more of the antibacterial components can also be used.

The virus inactivating component is not particularly limited, and is, for example, isopropylmethylphenol (IPMP), carbachlor, timol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol. , Orthophenylphenol, о-cresol, m-cresol, and p-cresol and other phenolic virus inactivating components, benzalconium chloride, benzalconium metosulfate, benzalconium organic acid salt and other benzalconium salts. , Benzethonium salt such as benzethonium chloride, benzethonium metosulfate, benzethonium organic acid salt, cetylpyridinium salt such as cetylpyridinium chloride, cetylpyridinium metosulfate, cetylpyridinium organic acid salt, didecyldimethylammonium chloride, decyldimethylammonium metosulfate, etc. Dilauryldimethylammonium salts such as didecyldimethylammonium salt, dilauryldimethylammonium chloride, dilauryldimethylammonium metosulfate, distearyldimethylammonium salts such as distearyldimethylammonium chloride, distearyldimethylammonium metosulfate, and 1,4. -Bis [3,3'-(1-decylpyridinium) methyloxy] butane dibromide, 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butanedichloride, 1,4-bis [ 1,4-Bis [3,3'-(1-decylpyridinium) methyloxy] butane salt such as 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butane dimethsulfate, etc. Inactivating components, bigwanide virus inactivating components, azole virus inactivating components such as tebuconazole and enylconazole, fruit seed extract-based viruses such as grapefruit seed extract, oyster seed extract, and grape seed extract. Inactivating component, glycerin monofatty acid ester-based virus inactivating component such as monolaurin, monocaprin, monocapriline, chlorhexidine salt such as chlorhexyzingulconate, chlorhexididi hydrochloride, chlorhexidine virus inactivating component such as chlorhexidine, octadecyldimethyl (3-Triethoxysilylpropyl) ammonium chloride, dodecyldimethyl (3-triethoxysilylpropyl) Cyrilpropyl) ammonium chloride, dodecyldiisopropyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldi-n -Propyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyldi-n-propyl (3-tri) Ethoxysilylpropyl) ammonium chloride, hexadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride , Octadecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, octadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride and other silicon-based virus inactivating components, benzoic acid, salicylic acid, sorbic acid, ethylenediamine tetra Carboxylic virus inactivating components such as acetic acid (EDTA), glycine, alkyldiethylaminoglycin, polylysine or salts thereof, dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, Examples thereof include silver-based virus inactivating components such as silver zeolite, zincpyrythion, thiamine lauryl sulfate, shirako protein, hydroxyalkylchitosan or a salt thereof. The virus-inactivating component can be used alone, or a component in which two or more of the virus-inactivating components are mixed can also be used.

The blending amount of the component (A) is preferably 0.01 to 10% by mass, more preferably 0.02 to 5% by mass, and 0.05 to 2% by mass in the effervescent medicinal effect-imparting composition. % Is more preferable.

The (B) surfactant used in the present invention may be any of an anionic surfactant, a nonionic surfactant, and an amphoteric surfactant. Examples of the anionic surfactant include alkylbenzene sulfonate, linear alkylbenzene sulfonate, alkyl sulfate, α-olefin sulfonate, alkyl phosphate ester salt, polyoxyethylene alkyl ether sulfate, and polyoxyethylene. Examples thereof include alkylphenyl ether sulfates and polyoxyethylene alkyl ether phosphates, and examples of the nonionic surfactant include polyoxyethylene oleyl ether, polyoxyethylene tridecyl ether, polyoxyethylene cetyl ether, and polyoxyethylene. Polyoxyethylene alkyl ether such as 2-ethylhexyl ether, polyoxyethylene polyoxypropylene alkyl ether such as polyoxyethylene polyoxypropylene cetyl ether, polyoxyethylene polyoxypropylene 2-ethylhexyl ether, polyoxyethylene alkylphenyl ether, poly Oxyethylene higher fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, fatty acid alkanolamide, lauryl polyglucoside, alkyl polyglucoside such as myristyl polyglucoside, palm oil fatty acid diethanolamide, polyoxyethylene hydrogenated castor oil, etc. Examples of the amphoteric surfactant include alkylamine oxide, coconut oil alkyldimethylamine oxide, betaine aminoacetate, amidopropylbetaine, alkylamidepropylhydroxysultane, 2-alkyl-N-carboxymethyl-N-hydroxy. Ethylimidazolinium betaine and the like can be mentioned. Among these surfactants, from the viewpoint of foamability, it is preferable to contain a nonionic surfactant and / or an amphoteric surfactant, and it is more preferable to contain a nonionic surfactant, and polyoxyethylene alkyl. It is more preferable to contain an ether and / or a polyoxyethylene polyoxypropylene alkyl ether, and even more preferably to contain a polyoxyethylene alkyl ether having a branched alkyl chain and / or a polyoxyethylene polyoxypropylene alkyl ether. These surfactants can be used in combination of one or more. Further, it is preferable that the surfactant (B) is blended in an amount of 0.1 to 10% by mass in the effervescent medicinal effect-imparting composition of the present invention. In addition, in this specification, a cationic surfactant which is an antifungal component, an antibacterial component, an antifouling component and a virus inactivating component shall not be treated as (B) a surfactant.

The solvent (C) used in the present invention is not particularly limited, and is, for example, a hydrocarbon solvent such as normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, vaseline, squalane, α-olefin oligomer, and squalane, and ethanol. , 1-propanol, 2-propanol (IPA), 1-butanol, 2-butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol and other alcoholic solvents, 2-phenoxyethanol ( Ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, tripropylene glycol monobutyl ether Glycol-based solvents such as, etc. may be mentioned. One or more of these solvents can be used in combination, and it is preferable that the solvent (C) is blended in an amount of 0.5 to 30% by mass in the effervescent medicinal effect-imparting composition of the present invention.

Examples of the water used in the present invention include purified water such as ion-exchanged water and reverse osmosis membrane water, ordinary tap water, industrial water, and deep ocean water. The blending amount of water is not particularly limited as long as the solubility is maintained, but it is preferable that 50 to 99% by mass of water is blended in the effervescent medicinal effect-imparting composition of the present invention.

Further, in the effervescent medicinal effect-imparting composition of the present invention, as other components, as necessary, an algae-proofing agent, a chelating agent such as sodium citrate, a pH adjuster such as citric acid, and a rust preventive agent such as sodium benzoate. Agents, blue dyes, green dyes, red dyes and other dyes, antifouling agents and the like may be appropriately blended as long as the effects of the present invention are not impaired.

In the present invention, when the effervescent medicinal effect-imparting composition is injected into a 300 mL graduated cylinder having a bottom area of 11.3 cm ² for 1 second, the maximum value X of the volume of foam immediately after injection and the foam 1 minute after injection are used. The bubble volume ratio, which is the ratio to the volume Y, is preferably Y / X ≦ 0.99, and more preferably Y / X ≦ 0.70. After injecting the effervescent medicinal effect-imparting composition of the present invention, the foam volume ratio, which is the rate of change in foam volume, is within the above range, so that the diffusivity of the active ingredient is improved and excellent medicinal effect can be exhibited. can.

The compounding mass ratio of the active ingredient (A) and the organic solvent (C) of the effervescent medicinal effect-imparting composition of the present invention is preferably 10 ≦ (C) / (A) ≦ 700, and 50 ≦ (C) / ( A) It is more preferable that ≦ 500. When (C) / (A) is within the above range, the diffusibility of the active ingredient is improved and excellent medicinal effect can be exhibited.

The pH of the effervescent medicinal effect-imparting composition of the present invention is preferably 5.0 to 12.0. As a result, it becomes weakly acidic to basic, and can be used for metals that are easily corroded by strong acids, resulting in a highly versatile effervescent medicinal effect-imparting composition.

The medicinal properties of the effervescent medicinal effect-imparting composition of the present invention differ depending on (A) the active ingredient. For example, when the component (A) is an aromatic deodorant component, it has an aromatic deodorant effect, when the component (A) is an antifungal component, it has an antifungal effect, and when the component (A) is an insecticidal component, it has an insecticidal effect, (A). When the component is an antifouling component, it has an antifouling effect, when the component (A) is an anti-slimy component, it has an anti-slimy effect, and when the component (A) is an antibacterial component, it has an antibacterial effect, and the component (A). However, the virus inactivating component is a virus inactivating effect. In addition, (A) when two or more kinds of ingredients are used as the active ingredient, the medicinal effect depends on the kind of the ingredient. For example, when the component (A) is an aromatic deodorant component and an insect repellent component, it has an aromatic deodorant effect and an insect repellent effect.

Further, the effervescent medicinal effect-imparting composition of the present invention may be a spray form in which a trigger type or pump type spray container is filled and does not require a propellant, or an aerosol form in which a pressure resistant container is filled and a propellant is mixed. Used as a spray product. In the latter, the aerosol stock solution is placed in an aerosol container, and the propellant is not particularly limited, but liquefied petroleum gas (LPG) such as propane, normal butane and isobutane, normal pentane, isopentan, dimethyl ether (DME), HFO1234ze and the like. Examples thereof include liquefied gas such as hydrofluoroolefin, compressed gas such as nitrogen gas, carbon dioxide gas, nitrous oxide, and compressed air, and the aerosol of the present invention can be provided by pressurizing and filling these. .. The aerosol can be a fixed-quantity injection type aerosol by providing a fixed-quantity injection valve. The blending ratio (volume ratio) of the aerosol stock solution and the propellant is preferably 10/90 to 60/40, more preferably 15/85 to 50/50, and 20/80 to 40/60. Is even more preferable. As the type of aerosol, either an aqueous aerosol or an oily aerosol can be formulated. Further, the number, dimensions and shapes of the nozzles in the spray form or the aerosol form are not particularly limited. The injection button may be any type of button that forms bubbles, but a spout type or a button having a mechanical breakup mechanism is preferable.

The treatment target of the effervescent medicinal effect-imparting composition of the present invention is not particularly limited, but is limited to toilet bowls, bathtubs, drain pipes, washing tubs, window glasses, air conditioner filters, filters, air conditioner aluminum fins, ventilation fans, net doors, and automobiles. From the viewpoint of easy spraying and processing, it is suitable for use in toilet bowls, bathtubs, drain pipes, washing tubs, and the like.

The present invention is not limited to the above-described embodiment, and various modifications can be made within the scope of the claims, and the embodiment obtained by appropriately combining the technical means disclosed in the different embodiments. Is also included in the technical scope of the present invention. Hereinafter, the effects of the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.

[Preparation of effervescent medicinal effect-imparting composition]
Fragrance A (lavender-like fragrance containing 15% d-limonene, 15% linalyl acetate, and 10% linalool) as a component (A), d-limonene, lavender oil, and polyoxyethylene 2-ethylhexyl ether (B) as a component. Hereinafter referred to as POE 2-ethylhexyl ether. Newcol 1008, manufactured by Nippon Emulsifier Co., Ltd., alkyl polyglucoside (10-16 carbon atoms, Glucopon 600 CSUP, manufactured by BASF Co., Ltd.), coconut oil alkyldimethylamine oxide (Cadenax DMC) -W, manufactured by Lion Specialty Chemicals Co., Ltd.), (C) components include ethanol (manufactured by Fuji Film Wako Junyaku Co., Ltd.), 2-phenoxyethanol (Dawanol EPh, manufactured by Ando Parachemy Co., Ltd.), 1-phenoxy- 2-Propanol (Dawanol PPh, manufactured by Dow Chemical Japan Co., Ltd.) is blended in the blending ratios (% by mass) shown in Tables 1 and 2, and ion-exchanged water is added to make 100% by mass to prepare an effervescent medicinal effect-imparting composition. It was adjusted. This effervescent medicinal effect-imparting composition was placed in an aerosol container together with LPG as a propellant to prepare aerosol products shown in Tables 1 and 2 (Examples 1 to 13). The injection button used was a button with a resin pipe (part number D94WHCD "3" -A-NP-23-100N-W, manufactured by Mitani Valve Co., Ltd.) with an inner diameter of 0.6 mm and a length of 10 cm. In addition, the temperature of each aerosol product is adjusted to 25 ° C in a water bath, and it is injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm ² for 1 second. The volume Y of the foam after minutes was read on each scale, the maximum value X of the volume and the volume Y were obtained, and the bubble volume ratio (X / Y) was measured.

Similarly, as a component (A), a fragrance A (lavender-like fragrance containing 15% d-limonene, 15% linalyl acetate, and 10% linalool), and as a component (B), POE 2-ethylhexyl ether (Newcol 1008, Japanese emulsifier). (Manufactured by Co., Ltd.) The composition [L] having an effervescent medicinal effect was adjusted to 100% by mass by blending in the blending ratio (% by mass) shown in Table 3 and adding ion-exchanged water. This effervescent medicinal effect-imparting composition [L] is placed in an aerosol container together with the propellant [G] (the volume ratio is [L] / [G] = 70/30), and the aerosol products shown in Table 3 are prepared. Prepared. For the injection button, a button with a resin pipe (part number D94WHCD "3" -A-NP-23-100N-W, manufactured by Mitani Valve Co., Ltd.) was used, which has an inner diameter of 0.6 mm and a length of 10 cm. In addition, the temperature of each aerosol product is adjusted to 25 ° C in a water bath, and it is injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm ² for 1 second. The volume Y of the foam after minutes was read on each scale, the maximum value X of the volume and the volume Y were obtained, and the bubble volume ratio (X / Y) was measured.

[Effect test 1 (test results are shown in Table 4)]
(1) Diffusibility test of aromatic deodorant component 1. Two stainless steel cylinders (diameter 20 cm, length 85 cm) were connected. The mouth at one end of the cylinder was previously covered with aluminum foil having a hole of about 7 cm square in the center (hereinafter referred to as the evaluation side). The mouth on the other side was left as it was without aluminum foil (hereinafter referred to as the sample side).
2. 2. 2. Spray the sample into a glass petri dish (diameter 9.8 cm, height 1.8 cm) with an open top for 1 second, put it inside from the sample side, and place it 10 cm from the end of the in-cylinder sample side. Immediately, the mouth of the cylinder on the sample side was covered with aluminum foil.
4. The evaluator continued to sniff the inside of the cylinder from the mouth of the evaluator, and measured the time from putting the glass petri dish to feeling the scent. The average measurement time was calculated by averaging the times measured by 10 evaluators, and evaluated according to the following criteria.
<Diffusivity of aromatic deodorant component>
⊚: (Average measurement time) ≤12 seconds 〇: 12 seconds <(Average measurement time) ≤17 seconds ×: 17 seconds <(Average measurement time)

(2) Medicinal effect (fragrance deodorant effect) test 1. Two stainless steel cylinders (diameter 20 cm, length 85 cm) were connected. One end of the cylinder is previously covered with aluminum foil having an opening (hereinafter referred to as opening A) in the lower half (hereinafter referred to as the sample side), and on the opposite side, 7 cm × in the center. The lid was covered with aluminum foil provided with a 7 cm opening (hereinafter referred to as opening B). (Hereafter, it will be referred to as the evaluation side.) Further, on the evaluation side, an aluminum foil having a size that hides the opening B was attached as a lid of the opening B, and by opening and closing this, the opening B could be opened and closed.
2. 2. Place 0.5 mL of 1% ammonia water on the top of the glass table (diameter 9.8 cm, height 1.8 cm), put it inside from the sample side of the stainless steel cylinder, and 10 cm from the end of the sample side in the cylinder. I put it in. In this state, the fan (manufactured by Nidec Servo, VE55B5) was switched on and air was blown for 10 seconds.
3. After 10 seconds, stop the fan, gently open the aluminum foil lid of the opening B on the evaluation side, have the evaluator smell the inside of the cylinder from the opening B, and smell the ammonia in 6 stages (0: odorless). , 1: Smell that can be finally perceived, 2: Smell that can be easily perceived, 3: Smell that can be easily perceived, 4: Strong odor, 5: Strong odor) ..
4. Take out the foul-smelling glass stand from the sample side, then inject the sample into a glass petri dish (diameter 9.8 cm, height 1.8 cm) with an open top for 1 second, put it in from the sample side, and put it in the in-cylinder sample side. It was placed 10 cm from the edge and allowed to stand for 10 seconds.
5. 3. Similarly, gently open the lid of the aluminum foil of the opening B on the evaluation side, have the evaluator smell the inside of the cylinder from the opening B, and smell the ammonia in 6 stages (0: odorless, 1: finally can be detected. It was evaluated by odor 2: weak odor that can be understood what odor it is, 3: easily perceptible odor, 4: strong odor, 5: strong odor) (the evaluation score is T).
6. The deodorizing rate of ammonia odor was calculated by (ST) / S × 100. The average deodorant rate was calculated by averaging the results of 10 evaluators, and evaluated according to the following criteria.
<Medicinal effect (fragrance deodorant effect) test>
⊚: 60% ≦ (average deodorant rate)
〇: 30% ≤ (average deodorant rate) <60%
×: (Average deodorant rate) <30%

(3) Foam performance test The foaming and popping method (feeling of use) when spraying various foaming medicinal effects-imparting compositions on a stainless steel plate was evaluated according to the following criteria.
<How to foam and pop (feeling of use)>
◎: Both foaming and popping are good 〇: Foam is hard to pop, or pops quickly and foam is hard to pop ×: Foam does not pop at all

As a result of the test, the foam is the ratio of the maximum value X of the volume of foam immediately after injection to the volume Y of foam 1 minute after injection when injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm ² for 1 second. Examples 1 to 13 having a volume ratio (Y / X) of Y / X ≦ 0.99 were excellent in the diffusivity of the aromatic deodorant component, the aromatic deodorant effect, and the usability. Among them, Examples 2 to 8 and 11 to 13 in which Y / X ≦ 0.70 were found to be more excellent in the diffusivity of the fragrance deodorant component, the fragrance deodorant effect, and the usability. On the other hand, in Comparative Example 1 which does not satisfy Y / X ≦ 0.99, favorable results were not obtained in any of the diffusivity of the fragrance deodorant component, the fragrance deodorant effect and the feeling of use.

[Effect test 2: Antifouling effect test]
(1) Test Example 1
In Example 5, instead of 0.05% by mass of the fragrance A, 0.05% by mass of the quaternary ammonium salt polymer compound which is an antifouling component is blended, and the others are the same as in Example 5 of Example 14. Obtained an aerosol product. The pH of the effervescent medicinal effect-imparting composition of this aerosol product was 6.0, and the foam volume ratio (Y / X) was 0.27.
The aerosol product of Example 14 was sprayed onto the toilet bowl for 1 second, left for 1 minute, and then flushed with water. When three drops of salad oil were dropped onto this treated toilet bowl and water was poured, all the vegetable oil flowed without sticking to the toilet bowl.

(2) Test Example 2
In Example 12, instead of 0.05% by mass of d-limonene, 0.05% by mass of a quaternary ammonium salt polymer compound which is an antifouling component was blended, and the other examples were the same as in Example 11. Fifteen aerosol products were obtained. The pH of the effervescent medicinal effect-imparting composition of this aerosol product was 6.4, and the foam volume ratio (Y / X) was 0.08.
The aerosol product of Example 15 was sprayed onto the toilet bowl for 1 second, left for 1 minute, and then flushed with water. When three drops of salad oil were dropped onto this treated toilet bowl and water was poured, all the vegetable oil flowed without sticking to the toilet bowl.

[Effect test 3: Antifungal effect test]
(1) Test Example 1
In Example 5, instead of 0.05% by mass of the fragrance A, 0.05% by mass of thymol was blended with an antifungal component to obtain an aerosol product of Example 16 in the same manner as in Example 5. The pH of the effervescent medicinal effect-imparting composition of this aerosol product was 6.0, and the foam volume ratio (Y / X) was 0.23.
When the aerosol product of Example 16 was sprayed onto the tiles in the bathroom for 1 second, left for 1 minute, then rinsed with water and left for 1 week, black mold and pink slime did not grow on the treated surface.

In Example 11, instead of 0.05% by mass of the fragrance A, 0.05% by mass of thymol, which is an antifungal component, was blended to obtain an aerosol product of Example 17 in the same manner as in Example 11. The pH of the effervescent medicinal effect-imparting composition of this aerosol product was 6.4, and the foam volume ratio (Y / X) was 0.09.
When the aerosol product of Example 17 was sprayed onto the tiles in the bathroom for 1 second, left for 1 minute, then rinsed with water and left for 1 week, black mold and pink slime did not grow on the treated surface.

The effervescent medicinal effect-imparting composition of the present invention is used in toilet bowls, bathtubs, drain pipes, washing tubs, windowpanes, air conditioner filters, filters, air conditioner aluminum fins, ventilation fans, screen doors, automobiles, etc. Since it is possible to improve the diffusivity and medicinal effect of active ingredients such as antifouling component, antifungal component, antibacterial component, and virus inactivating component, it may be used for injection products having these medicinal properties.

Claims (13)

In an effervescent medicinal effect composition for filling a jet product,
The composition contains (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water.
It is a ratio of the maximum value X of the volume of foam immediately after injection and the volume Y of foam 1 minute after injection when the composition is injected into a 300 mL graduated cylinder having a bottom area of 11.3 cm ² for 1 second. An effervescent medicinal effect-imparting composition having a foam volume ratio of Y / X ≦ 0.99. The effervescent medicinal effect-imparting composition according to claim 1, wherein the organic solvent (C) is one or more selected from the group consisting of a hydrocarbon solvent, an alcohol solvent, and a glycol solvent. The effervescent medicinal effect-imparting composition according to claim 1 or 2, wherein the organic solvent (C) is blended in an amount of 0.5 to 30% by mass. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 3, wherein the compounding mass ratio of the (A) active ingredient and the (C) organic solvent is 10 ≦ (C) / (A) ≦ 700. .. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 4, wherein Y / X is Y / X ≦ 0.70. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 5, wherein the pH of the composition is 5.0 to 12.0. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 6, wherein the surfactant is a nonionic surfactant and / or an amphoteric surfactant. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 7, wherein the active ingredient (A) is an aromatic deodorant component and the medicinal effect is an aromatic deodorant effect. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 7, wherein the active ingredient (A) is an antifouling ingredient and the medicinal effect is an antifouling effect. The effervescent medicinal effect-imparting composition according to any one of claims 1 to 7, wherein the active ingredient (A) is an antifungal ingredient and the medicinal effect is an antifungal effect. An aerosol product obtained by filling an aerosol container with the composition according to any one of claims 1 to 10 and a propellant. A spray product obtained by filling a spray container with the composition according to any one of claims 1 to 10. An effervescent medicinal effect-imparting composition containing (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water.
It is a ratio of the maximum value X of the volume of foam immediately after injection and the volume Y of foam 1 minute after injection when the composition is injected into a 300 mL graduated cylinder having a bottom area of 11.3 cm ² for 1 second. A method for imparting a medicinal effect by injecting an effervescent medicinal effect-imparting composition having a foam volume ratio of Y / X ≦ 0.99.